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ABSTRACT 
Δ9-Tetrahydrocannabinol (THC) is the most psychoactive substance out of the over 80 
active cannabinoids. Due to its psychoactive and impairing properties, detection and 
quantitation is important to determine impairment levels of individuals. With an increased 
use of recreational marijuana, the risk of Driving Under the Influence of Drugs (DUID) is 
steadily increasing. Current legislation outlaws driving under the influence of Marijuana 
however there exists limitations with current methods of detection of drug analyte. Δ9-
Tetrahydrocannabinol, 11-Hydroxy- THC, and 11-nor-carboxy-THC, were used in 
detection because these analytes are produced in the metabolism of THC. Since THC is 
very lipid soluble, it is present in lipid rich environments in the body. Due to the lipid rich 
nature of meibomian fluid, a component of tears, and the presence of Fatty Acid Binding 
Protein (5) FAPB5, a protein known to bind to cannabinoids, tear fluid could be used as a 
less-invasive biological matrix to test for the presence of THC and its metabolites. 
 This project optimized a collection of tear fluid, along with a simple buffer 
extraction, to create a method suitable for direct injection using LC-MS/MS. Collection 
was completed by BVI Weck-Cel Sterile Cellulose strips, measuring approximately 2 x 
20 mm, and placed in Thompson eXtreme PVDF 0.2 m, pre-slit, red cap, filter vials 
containing Quantisal buffer solution for extraction. All analysis and calibrations were 
vi 
completed with fortified matrix standards with concentrations ranging from 0.25 - 250 
ng/mL. Validation was consistent with American Academy of Forensic Sciences Academy 
Standards Board (ASB) Standards of Forensic Toxicology Standard 036, First Edition 
2018.  
 Tear samples were collected from volunteer patients according to Institutional 
Review Board (IRB) standards before and after administration of Marijuana. Samples were 
collected approximately 30 minutes post administration in order to capture tears when the 
analyte is most potent in the body. Samples and calibration standards were analyzed using 
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) with the QSight® 220 
CR LC-MS/MS and the Halo® C18 3.0x50 mm (2.7 µm) column. Limit of Detection 
(LOD) and Limit of Quantitation (LOQ) for THC was calculated at 0.25 ng/mL. Limit of 
Detection of THCOOH was detected at 0.25 ng/mL and Limit of Quantitation was 
calculated at 1 ng/mL.  
 Upon analysis of Patient Samples, it was determined that THC and 
metabolites could be detected and quantitated in tear fluid. However, it is noted that 
insufficient sample volume in collection of this type of sample is an issue that leads to poor 
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Δ9-Tetrahydrocannabinol (THC) is the primary psychoactive compound in 
Marijuana that creates adverse, impairing effects for the user. Concentration of analyte is 
determined through toxicological analysis of biological fluids, also referred to as matrices 
In current practice, blood and urine are matrices primarily used for the detection of THC. 
However, there are inherent limitations in using these matrices even though they are used 
with the primary methods for determination of Driving Under the Influence of Drugs 
(DUID). The legalization and decriminalization of Marijuana on a state and federal level 
has raised questions for impaired driving statutes, specifically DUID. In current practice, 
there is variation in legislation as to what is a legal limit of operating a motor vehicle while 
under the influence of Marijuana1.  
A good matrix used in detection of drug analytes involving DUID should be able 
to determine concentration at the time of a roadside stop. The current inherent issue with 
blood is the nature of time sensitivity as an invasive method. In order to collect a sample, 
the sample cannot be collected roadside and must be done by a certified phlebotomist. The 
meibomian lipids within tear samples are hypothesized to be an efficient matrix for the 
detection of THC due to the lipophilic nature of THC and could reduce the limitations of 






 It has been reported that cannabis use has progressively increased over the past 
decade2. Consumption varies among individuals, both in terms of method of consumption 
and frequency of consumption1. Cannabis, contains over 421 chemical compounds and 
over 60 cannabinoids, with more being discovered3. Within the classification of 
Cannabinoids exists the sub-category of THC.  Δ9-Tetrahydrocannabinol is contained in 
the fruits, leaves and resin of the plant matter of Cannabis Sativa4. Approximately 95% of 
THC found within Cannabis are a combination of monocarboxylic acids that are subject to 
decarboxylation when heated4. When decarboxylated, due to heating or drying, THC is 
absorbed in the body and the user is able to feel the psychoactive effects4. 
 THC has 9 known cannabinoids with C1-C5 side chains3,5. THC precursors can be 
designated into two categories: Δ9-Tetrahydrocannabinolic acid A (THCA-A) and Δ9-
Tetrahydrocannabinolic acid B (THCA-B). These two categories represent the biogenic 
precursors, THCA-A being the major precursor and THCA-B being the minor precursor, 
being available at a much lesser percent5.  
 
1.2.1 Pharmacodynamics of Δ9-Tetrahydrocannabinol 
 Δ9-Tetrahydrocannabinol is a cannabinoid with psychoactive properties, meaning 
that the compound has the capacity to alter the mental state6. THC has been shown to alter 
vital processes such as increased heart rate, as well as alter subjective processes. Effects 
include: creating dysphoria and  euphoria, increased somatic effects, a mimic of stimulant 
effects, as well as alteration of intellectual efficiency and energy7. Mentioned in Effects of 
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THC on Behavioral Measures of Impulsivity in Humans (McDonald et al.), THC is more 
sedative in nature and shares this parallel with ethanol7. Marijuana has been known to have 
therapeutic effects as THC and Cannabidiol (CBD) have been utilized for anti-convulsion, 
analgesic, hypnotic, anti-emetic, and anxiolytic properties8,9.  
Cannabinoids effect natural processes by interacting with endogenous cannabinoid 
receptors10,11. Distribution of specific receptors have been linked to the cerebral cortex, 
limbic areas, basal ganglia, cerebellum, thalamus, and brainstem10. In turn, Cannabis 
effects approximately every system in the body and effects both mood and cognition. As 
stated previously, THC is sedative in nature and produces what is described as a “high” or 
extreme euphoria. The high can occur seemingly instantly and can reach a plateau in which 
the effects could last 2 hours or more10. Spatial perception is altered when under the 
influence of THC and psychomotor performance is significantly impaired10. This is aligned 
with a dampened reaction time, impaired perception, motor incoordination, short term 
memory alteration, and issues in concentration10. 
 
1.2.2 Pharmacokinetics of Δ9-Tetrahydrocannabinol 
 Δ9-Tetrahydrocannabinol can be administered in different ways. The most 
common practice of administration is smoking. Smoking creates a simplistic and efficient 
way to administer THC because of the direct heating of the Marijuana. Smoking produces 
a rapid method of drug delivery to the Central Nervous System 4,12.  Within seconds of 
inhalation, THC can be measured in plasma4. THC can be administered orally and is 
absorbed due to its high octanol/water partition coefficient12. THC has been administered 
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rectally, sublingually, and dermally although these are not common routes of 
administration12.  
Smoking in common practice allows approximately 20-25% of the inhaled THC to 
be biologically available. It has been determined by Marilyn A. Huestis that an actual dose 
of 0.2 to 4.4 mg of 100% THC is enough to cause psychoactive effects12. This was 
calculated by taking distribution data, discovered by Adams and Martin in 199613. Their 
study outlined a dose of 2 to 22 mg, however this did not account for the approximate 75-
80% loss13,14. THC distribution is a rapid process because of its affinity to lipid rich areas 
and metabolism by the liver. The heart, lungs, brain, and the liver are lipid rich organs that 
receive the THC well because of its lipophilicity14.   THC has a high volume of distribution 
at approximately 10 l/kg and it is 95-99% protein bound to lipoproteins in plasma14,15. 
When exposed for a long period of time, concentrations of THC are significantly increased 
in the body’s fat molecules and can be retained for extended periods of time14,16. 
THC is metabolized through hepatic metabolism in two phases14. Phase I is an 
oxidation of the THC in which the molecule undergoes allylic and aliphatic hydroxylation, 
oxidation of ketones and alcohols, beta-oxidation, and degradation of the pentyl side 
chain14. Phase II is a glucuronidation reaction14. All pathways are visualized in Figure 1. 
The metabolism of THC yields an equally potent metabolite, 11-hydroxy-THC (11-OH-
THC) as well as an inactive metabolite, 11-nor-9-carboxy-THC (THCCOOH), both of 





Figure 1.  Metabolic process of THC19 
 
1.2.3 Δ9-Tetrahydrocannabinol Affinity to Lipids 
 As seen in section 1.2.2, the nature of distribution of THC is extremely rapid and 
lipid focused. As stated before, THC has an affinity to lipid rich tissues and fluids such as  
brain, lung, liver, plasma, and other adipose tissues14. Normally, the lipophilic nature of 
THC and other cannabinoids pose problems for detection because it imposes a limitation 
on what materials, procedures, and matrices can be utilized. It would be of extreme benefit 
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to optimize a detection procedure that utilizes a lipid rich matrix that is non-invasive of 
nature for sample collection . 
 
1.3 Ophthalmology: Meibomian layer of tear fluid as a probative matrix 
1.3.1 Tear Composition  
It is our hypothesis that THC and its metabolites can be detected from tear fluid due 
to the lipid rich nature. The matrix itself is made from the mixture of secretion of glands 
within the eye lids20. Meibomian glands, also referred to as tarsal glands, are long 
sebaceous glands that are situated in tarsal plates of the eyelid21. There are approximately 
45 glands per eye (25 in the upper lid, 20 in the lower lid) that maintain a central canal that 
secrete sebum, a lipid rich secretion. Meibomian glands are holocrine, meaning that lipids 
are secreted by the action of cell degradation. The purpose of these secretions are to create 
an oily film over the eye21. Tear layers are structured as an inner-mucin enriched mucous 
layer, a middle aqueous layer, and the outer lipid layer secreted from the meibomian 
glands21.  
This layer has a function of stability as it reduces the surface tension controlling 
evaporation22. This keeps the eye moisture in a relatively stable condition and also prevents 
the intrusion of bacteria into the eye itself20. The primary phospholipid in meibomian fluid 
is phosphatidylcholine (Figure 2), however, other phospholipids are important, such as 
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phosphatidylserine (Figure 3) which is important to formation of polar lipid 
monolayers20,23,24. 
Figure 2.  Structure of 
phosphatidylcholine20 




There is current evidence that suggests that the meibomian glands are controlled by 
neuronal, hormonal, and vascular stimulus20.  
 
1.3.2 Proteomics of tear fluid: Relevance to Δ9-Tetrahydrocannabinol 
 Pharmacokinetic study shows that THC is absorbed into lipid heavy areas of the 
body: heart, lung, brain, etc26. THC is transported throughout the body by specific 
lipoproteins and is activated by cannabinoid receptors CB1 and CB2, located mainly in the 
brain26. It has been shown, in Elmes et al., that at least three fatty acid binding proteins 
(FABPs) bind THC and CBD26. In the study, computational data was examined to 
determine the likelihood of THC and CBD binding to FABPs. Energy scores were 
consistent with probable binding to FABPs: FABP3, FABP5, and FABP7. These three 
FABPs are genetic variants of FABPs26. FABP5 is also known as Epidermal-Fatty Acid 
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Binding Protein thought to aid in the fatty acid uptake transport and metabolism. FABP5 
is found in epidermal cells 27. 
 FABP5 has been shown to be efficient in use as a biomarker for diseases such as 
Dry Eye Disease (DED). In a study conducted by Shinzawa et al., FABP5 was measured 
in tear fluid by Enzyme Linked Immunosorbent Assay (ELISA) and was found to be 4076 
± 5746 pg/mL in a group of 12 healthy control individuals27. FABP5 can be found in the 
brain, liver, and kidneys, all tissues that have been known to store THC and 
metabolites14,27. The use of biomarkers for ophthalmological disease is not currently 
relevant to this study, however the presence of FABP5 in tear fluid could be related. It is 
hypothesized that THC and its metabolites would be detectable in meibomian layer of tear 
composition for its affinity to lipid rich media.  This hypothesis is strengthened through 
the presence of FABP5 within tear fluid and a known interaction between FABP5 with 
THC and other cannabinoids. 
 
1.4 Legality of Marijuana and DUID 
 
The legalization of Marijuana state by state is complex as there is varying 
legislation. In bill H.R. 1588, sponsored by Representative Gabbard, there is a current 
movement to strike Marijuana from the Controlled Substances Act (21. U.S.C. 801 et 
seq.)28.  Marijuana is currently listed on the Controlled Substances Act as a Schedule 1 
substance, meaning there is high potential for abuse with no widely accepted medical use29.  
With the current surge of Marijuana use, decriminalization of Marijuana would 
likely continue to lead to another increase in Marijuana usage. An inflation of marijuana 
use would pose issues in terms of motor vehicle operation. Laboratory studies indicate that 
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operating a vehicle under the influence of marijuana slows reaction time, reduces the ability 
to divide attention, and impairs ones concentration and coordination30,31.  
There are complications with the analysis of driving under the influence of 
Marijuana cases such as the fact that those who are involved on auto accidents may be 
under the influence of multiple substances at the time and therefore the control groups for 
analysis are difficult30. Regardless, operation of a motor vehicle when one’s perception and 
reaction time is impaired should be prevented. 
 
1.4.1 State by State DUID Prevention 
Regardless of Federal legality, Marijuana is treated differently state by state as it is 
recognized as a psychoactive substance that leads to impairment. State legislation has 
increasingly made strides to use specific wording to address impaired driving when 
influenced by substances other than alcohol1. When under the influence of Marijuana, it is 
illegal to operate a motor vehicle. Yet, states utilize three different types of legislative 
terminology when it comes to DUID. The first is the “incapable” terminology, which forces 
the state to prove that the illicit substance caused the impaired driving1. The second 
terminology is “under the influence”. Like the term “incapable” the term “under the 
influence” forces the state to prove to the court that the drug was the reason for the impaired 
driving1.These examples of terminology emphasize the burden of proof in cases of DUID. 
The final terminology is known as “per se.” Per se laws are similar to existing measures of 
blood alcohol concentration (BAC) in which a designated concentration of drug or drug 
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metabolite will be the zero tolerance threshold in determination of legal operation of a 
vehicle1.  
Per se laws have inherent issues in their wording and application to legislation and 
law enforcement. The idea of zero tolerance works for legal substances that have impairing 
properties. Operating a motor vehicle under the influence of alcohol is considered illegal 
under the basis that the individual is operating over a designated limit. States have differing 
legislation surrounding legalization of marijuana. This means if a state has a zero-tolerance 
policy as well as legislation that criminalizes the possession and intoxication of marijuana, 
any concentration will be deemed as impairing1. On the contrary, states with per se laws 
and legalized marijuana, they then have the ability to create concentration limits30 for 
impairment. 
 
1.5 Research Objective 
 Marijuana use is becoming more and more prevalent on the basis of alteration of 
current legislation. There is a possible need for technology to assist in the assessment of 
impairment in DUID cases. As Marijuana use adversely effects a person’s ability to operate 
a motor vehicle safely, there is an emerging need for accurate and simplified methods to 
detect concentrations of drug and drug metabolites in subjects of DUID. As previously 
stated, there are inherent complications with the current matrices of toxicological analysis, 
blood and urine. THC and its metabolites, being lipophilic in nature, are hypothesized to 
be detectable in tear fluid. This hypothesis is strengthened by knowledge of the lipid rich 
meibomian layer of tears as well as existing proteomic studies of FABP5. The ultimate 
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purpose of this research is to explore the possibility of using tear fluid as a matrix to support 




2. MATERIALS AND METHODS 
2.1 Instrumentation Theory 
2.1.1 Liquid Chromatography 
 Chromatography is a method that separates the target analytes of interest from the 
overall mixture. Any sample that is submitted for detection has either already been through 
the purification/extraction process or has been deemed ready for analysis. Chromatography 
separates components of samples through the utilization of a mobile phase and a stationary 
phase. The mobile phase is a medium that transports the input sample through the system. 
The stationary phase is a packed column that the mobile phase and sample flow through. 
Drug analytes have different structures, and therefore variations of polarity and structure, 
the stationary phase will allow the analytes within the sample to adsorb to its surface with 
alternate affinities. Sample analytes with varying affinities for the stationary phase will 
move through the stationary phase at specified rates, resulting in separation32. In other 
words, differing chemical attractions drive the separation mechanism of Chromatography.  
There are two types of chromatography, Gas Chromatography (GC) and Liquid 
Chromatography (LC). The main difference between the two methods is the type of mobile 
phase where LC utilizes a liquid mobile phase and GC uses a gaseous mobile phase. 
However, a benefit to LC, specifically High Pressure Liquid Chromatography (HPLC), is 
its ease of use with non-volatile compounds32. The mobile phase conditions used in LC can 
be altered to enhance the resolution of target compounds and results. LC instruments can 
introduce a combination of mobile phases and washes. Most procedures utilize two paired 
solvents rather than one, allowing the user to utilize different ratios of mobile phase 
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introduced at a given time32. Each ratio of mobile phase is indicative of the parameters set 
by the user in order to obtain specific ratios of aqueous or organic solvents32.  
 Stationary and mobile phase conditions differ due to the nature of the necessary 
separation. The two designations of conditions are known as “normal” and “reverse-phase” 
conditions. Normal conditions are the original condition set in which the mobile phase is a 
non-polar solution and the column, or stationary phase, consisted of polar components. 
Reverse phase switches these conditions and utilizes a non-polar stationary phase and a 
polar mobile phase32. This technology and difference in phase conditions allows the user 
to be more adaptive to their specific analyte of interest.   
 
2.1.2 Mass Spectrometry 
 Once separated, the injected sample along with the analytes of interest must be 
detected. Samples separated from LC or GC are passed through different detectors in order 
to record elution times. A Mass Spectrometer is a detector that, in order of procedure, 
follows elution from the LC or GC column. To complete analysis by Mass Spectrometry 
(MS), analyte molecules must be converted to gas phase ions. Ions can be manipulated by 
in the mass spectrometer by magnetic and electrostatic fields. Mass Spectrometry 
completes detection through ionization and separation of mass to charge (m/z) ratio of the 
produced ions. A m/z ratio will show relative abundance of signals gathered from unique 
ion fragments33. The separation is made possible by utilization of the magnetic and 
electrostatic fields that can separate both fragment molecules and change the path of ions, 
thus preventing or directing the ions to the detection mechanism33. 
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 A mass spectrometer is composed of five main parts: ion source, inlet, mass 
analyzer, detector, and data system33. The ion source induces a repulsion that ionizes the 
molecule33. There exists different versions of ion sources that yield different types of 
ionization. This procedure utilizes an Electrospray Ionization (ESI) technique. ESI begins 
by introducing sample in solution form, by either eluent flow or direct infusion, and is then 
converting the sample into the gas phase. ESI utilizes electromagnetic fields and heated 
pressurized nitrogen gas to ionize the sample and utilizes electric fields to transfer ions 
from its solution to the gas phase34,35. ESI is classified as a “soft” ionization technique, 
meaning there is less fragmentation34. The ionization product in methods that are not “soft” 
methods will create smaller fragments at a greater multitude34.  
The ion plume travels to the mass analyzer which segregates ions based on their 
m/z ratio. The quadrupole consists of four rods that run parallel to one another fashioned 
like four points of a square, as seen in Figure 436. These rods create a route that the ions 
are moved through by alternating positive and negative frequencies36. By outputting 
specific frequencies between the rods, the ions either pass through the center of the rods or 
are diverted out resulting in further separation33. Some mass spectrometers utilize tandem 
mass spectrometry (MS/MS) which is a utilize two or more quadrupole mass analyzers to 




Figure 4.  Quadrupole Mass Analyzer pole orientation36 
 
2.1.3 Sample Preparation 
Sample preparation is a critical part of analyte analysis and detection. This process 
occurs before the analytical process to ensure the sample is compatible with the 
instrumentation or improve its performance. At its core, sample preparation is a chemical 
or physical modification to a sample. The sample usually consisted of two components: the 
analyte and matrix37. In the case of this study the analytes of interest are THC, and its 
primary metabolites THCCOOH and 11-OH-THC. The matrix was the collected tear fluid. 
A sample preparation method was utilized in this procedure to effectively filter target 









2.2 Instrumentation, Samples, and Reagents 
2.2.1 LC-MS/MS Instrumentation 
 Analysis was conducted by usage of the QSight® 220 CR LC-MS/MS 
(PerkinElmer,Waltham, Massachusetts, USA). Data was collected and quantified with 
PerkinElmer Simplicity 3Q™ Software (version 1.6.1903.11142). 
2.2.2 Patient Samples 
 
Patient samples were collected from four participants between the ages of 21-40. 
All samples were collected and donated in accordance with International Review Board 
(IRB) Standards in a collaborative effort with IMMAD (Quincy, Mass, USA) and Boston 
University School of Medicine Biomedical Forensic Science Program (Boston, 
Massachusetts, USA). All participants were required to fill out a marijuana questionnaire 
to obtain necessary information regarding their current usage. Questionnaire can be found 
in Appendix B. Participants were responsible for having their own recreational or 
medicinal Marijuana to achieve detectible levels of THC, adhering to IRB standards. All 
dosing was completed through the smoking route of administration.  
Blood samples, heart rate, and blood pressure were taken as a baseline measurement 
for both precautionary measures and biomarkers for changes in matrix and physiological 
response. Patient tear samples were collected with IRB approved, BVI Weck-Cel Sterile 
Cellulose strips (Beaver-Visitec International, Waltham, Massachusetts, USA), measuring 
approximately 2 x 20 mm. The cellulose strip was placed in the lower eyelid, one in each 
eyelid, for 10 seconds to allow for saturation. The strips were placed in Thompson Filter 
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Vials  (Thomson Instrument Company Oceanside, California, USA) containing 300 µL of 




Figure 5. Tear Collection with BVI Weck-Cel® Cellulose strips: A) Cellulose strip 




Drug standards and deuterated internal standards were purchased from Cayman 
Chemical Company (Ann Arbor, Michigan, USA) and Cerilliant - Certified Reference 
Materials (Round Rock, Texas, USA). Lot numbers can be seen in Table 1. Lab grade 0.9% 
Saline solution was used as synthetic tear fluid. NaCl was purchased from Fisher Scientific 
(Fair Lawn, New Jersey, USA). Optima grade acetonitrile (ACN), and Optima grade 
methanol (MeOH) were purchased from Fisher Scientific. Extraction buffer was obtained 
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from Immunalysis Quantisal™ (Pomona, CA, USA). Deionized (DI) water in this study 
was from an Ultrapure (Type 1) water system purchased from Millipore Sigma (Burlington, 
Massachusetts, USA). Formic acid used in mobile phases was purchased from Sigma-
Aldrich (St. Louis, Missouri, USA). 
 
Table 1. Certified Reference Standards 
 
Standard Lot Number 
THC 0581756 - Cayman 
11-OH-THC 0548589 - Cayman 
THCCOOH 0577400 - Cayman 
THC-D3 0583658 - Cayman 
11-OH-THC – D3 FE01031903 - Cerilliant 




2.3.1 LC-MS/MS Parameters 
Separation using the QSight® 220 CR LC-MS/MS was performed with the Halo® 
C18 3.0x50 mm (MAC-MOD, Chadds Ford, Pennsylvania) (2.7 µm) column. A mobile 
phase binary gradient of 0.1 Formic Acid in DI Water (Mobile Phase A) and 0.1% Formic 
Acid in acetonitrile (Mobile Phase B) was utilized through full loop injection. All 
parameters can be found in Table 2. Parameters were referenced from Gardner, 202038. ESI 
in positive ionization mode was utilized for analysis of analytes. All source conditions are 
outlined in Table 3 and all multiple reaction monitoring (MRM) transition parameters for 




Table 2. LC Method Conditions 
 
Time (Min) Rate (mL/Min) A(%) B% 
0.00 0.80 70 30 
0.50 0.80 70 30 
5.00 0.80 10 90 
8.51 0.80 70 30 
10.50 0.80 70 30 
Column Temperature: 40℃ 
Injection Volume (Full Loop): 20 µl 
 
 
Table 3. MS source conditions 
 
Source Perameter Specified Value 
Ionizaton Mode Positive 
ESI Voltage (V) 5850 
HSID™ Temp ℃ 200 
Nebulizer Gas 300 
Source Temp (℃) 250 





























315.3 193.4 Qualifier THC-D3 -56 -31 46 
315..3 123.3 Quantifier THC-D3 -71 -44 45 
11-OH-
THC 
331.1 313.4 Quantifier 
11-OH-
THC 
-52 -19 43 
331.1 193.1 Qualifier 
11-OH-
THC -60 -32 41 
THCCOOH 
345.2 327.3 Quantifier 
11-OH-
THC -53 -21 41 
345.2 299.4 Qualifier 
11-OH-
THC -65 -25 47 
THC- D3 328.3 123.3 IS  -71 -44 45 
11-OH-
THC D3 
334 196.1 IS  -60 -32 41 
21 
 
2.3.2 Filter Vial Separation  
 Standards of the analytes of interest at 1 mg/mL , THC, 11-OH-THC, and 
THCCOOH, were obtained and diluted to 10 µg/mL with methanol. This 10 µg/mL 
dilution was used to further dilute into both 1 µg/mL and 100 ng/mL solutions to be used 
as working stock solutions. Internal standard working stock was created with deuterated 
internal standards. Each internal standard was diluted with methanol to 100 ng/mL. The 
internal standard solution was ultimately diluted to a concentration of 1g/mL. 
 To create calibration standards, saline solution was used to replicate blank tear 
matrix. 200 µL of saline was spiked with specific concentrations of working stock solution 
to evaluate different concentrations of drug analyte within tear fluid. This fluid was then 
absorbed with two BVI Weck-Cel Sterile Cellulose strips, measuring approximately 2 x 
20 mm, and placed in Thompson eXtreme PVDF 0.2 m, pre-slit, red cap, filter vials 
containing Quantisal buffer solution. This was left for 30 min to aid in extraction. 30 L 
of 1g/mL internal standard was added and the vials were then compressed forcing the 
fluid and analyte through the filter as seen in Figure 6.  
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Figure 6. Collection and use of filter vials: A) cellulose strip is placed into the bottom 
portion of the vial B) Top portion, with the filter, is introduced and compressed with the 
bottom portion C) Analyte collected in the cellulose is forced through the filter in the top 
portion as the cellulose is left in the bottom portion. 
 
2.3.3 Patient Sample Collection 
  
 Patient baseline samples were collected with cellulose collection material cut small 
enough to be left in the volunteer’s lower eyelid. The cellulose material was left for 
approximately 10 seconds to induce complete saturation of the material. The material 
collected was then placed in Thompson filter vials containing extraction buffer and placed 
in the freezer at -20C. Volunteers, once produced baseline data was acquired, were asked 
to dose themselves and return to the testing area within a 30-minute time interval to allow 
for peak concentrations of THC and metabolites. Upon arrival to the designated testing 
area, participants were tested again for heart rate and blood pressure, and asked to provide 
data on physiological changes. Blood was drawn as well. The same cellulose testing 
material was utilized to collect the evidentiary tear fluid to the same parameters. Similarly, 
the material was placed in Thompson filter vials containing extraction buffer and stored in 
a freezer until ready for analysis. 
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2.3.4 Method Validation 
 
2.3.4.1 Calibration Model 
 
 For this procedure, it was important to understand the relationship between 
available concentration of material and ability to detect the target analytes. Determined 
from 5 separate runs, the Calibration model used 9 data points of varying concentrations: 
0.5, 1, 2, 5, 10, 20 50, 100, and 250 ng/mL. Baseline calibration data was gathered by 
spiking 200 ul of saline solution for each calibrator on point at these specific 
concentrations. This style of procedure yields a calibration curve that provides an image of 
plotted concentration in comparison to analyte peak area to internal standard peak area. 
 
 
2.3.4.2 Limit of Detection/Limit of Quantitation 
  
Working with a novel matrix it is important to understand the complexities of 
detecting drug analyte. Five batches of prepared calibrators were run through LC-MS/MS 
standard procedure to evaluate the ability to detect target analyte at known concentrations. 
A Limit of Detection (LOD) was determined by examining the 9 data points seen in Section 
2.3.4.1. The lowest point in which the method was able to detect a concentration of analyte, 
reliably and accurately, was the LOD. Limit of Quantitation is the lowest analyte 
concentration that can be reliably and accurately quantitated. Limit of Quantitation was 
analyzed using samples from the same 9 data point concentrations.  
 
2.3.4.3 Ion Suppression/Enhancement 
 
 When coeluting compounds on the same run, there can exist ion suppression or 
enhancement that can alter the expected results of the data set. In order to account for ion 
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suppression and enhancement, a minimum of 10 blank patient samples should be collected 
and analyzed for any presence of ion signaling. Especially with a novel matrix, it is crucial 
to the detection of analyte that there is no interference nor unexpected signal. The 10 blank 
samples consisted of tears are collected in the same fashion of the patient samples. The 10 




 When running samples, high concentrations of analyte may be detectable in 
subsequent samples. For this reason, carryover can negatively alter qualitative and 
quantitative analysis. This occurrence is not an intended result and steps were taken to 
mitigate this response. Vials with no analyte present, or blanks, were strategically placed 























3. RESULTS  
Results were processed in two parts: calibration and analysis of patient samples. 
All calibration data was prepared through the procedure in section 2.3.2. All patient 
samples were collected according to procedure listed in section 2.3.3. Patient samples were 
placed in 300 µl of extraction buffer. Calibration standards were stored in the same manner.  
 
3.1 Analyte Detection and Separation 
 Chromatographic Separation of analytes was completed by using a Halo® C18 3.0 
x 50 mm 2.7 µm LC column. Each analyte maintained a specific retention time confirmed 
by retention time of the internal standards and known retention time of target analytes. This 
data can be found in Table 5 and seen in Figure 7. THC-D3 was used as the internal 
standard for THC. The internal standard 11-OH-THC-D3 was used for both 11-OH-THC 
and THCCOOH due to the extreme similarities in retention time.  
 
Table 5. Average Retention Time: Compounds & Internal Standards 
 










Figure 7: Analyte Peak References 
 
 
3.2 Method Validation 
3.2.1 Dynamic Range 
 
 The dynamic range was determined for the model of calibration for the analytes of 
interest. The purposed of this range was to establish a correlation between the concentration 
of analyte and signal response. A quality dynamic range for an analysis of matrix should 
express a direct relationship between signal intensity and analyte. Although a dynamic 
range can be expressed linearly, a relationship can also be non-linear in nature39. The range 
was assessed for the procedure to produce a correlation between signal intensity and 
concentration.  
It was determined in previous work, Detection and quantitation of cannabidiol and 
delta (9) tetrahydrocannabinol in oral fluid of a therapeutic-use cannabidiol donor using 
the Qsight 220 CR LC-MS/MS, by Jenna Gardner, a stable working range for detection of 
THC in oral fluid ranged between 0.25 – 500 ng/ml in oral fluid38. This was determined by 
assessing previous studies, workplace drug testing limits, and published data of presence 
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of analytes in the body38.  This working range was altered due to the low sample volume 
of tear fluid in comparison to the sample volume in collected oral fluid.  
Due to the low sample volume, adding more data points to and shortening the range 
to 0.5 - 250 ng/mL was deemed a benefit to the procedure. A working range for tears was 
set at 0.5, 1, 2, 5, 10, 20, 50, 100, 250 ng/mL. Sample volume in the collection of tear fluid 
is an added variable that was addressed. Despite having theory to back up the presence of 
THC within tear fluid itself, collection of matrix for the purpose of detecting cannabinoid 
analytes was novel. The cellulose collection strips used collected approximately 200 ul of 
sample volume. This was used as the baseline sample volume for the calibration curve. 
Variability in collected sample volume from patients is a hindrance that effects the 
accuracy of data. 
A calibration model was set from five separate runs of calibration standards 
following the working range. Out of all of the calibrators, five out of the nine must have 
been of a permissible sample accuracy, ±20% deviation from 100% accuracy, to be an 
effective working curve. It was determined that analytes followed an exponential fit pattern 
and all average coefficient of variation (R2) values were calculated and were > 0.99. 
THCCOOH followed an interesting fit pattern as it appeared linear in nature. However, 
calculated R2 value was an acceptable 0.9922 when a quadratic fit was applied. All charts 








Figure 8: THC Standard Curve 
 





























3.2.2 Limit of Detection & Limit of Quantitation 
 
Limit of detection (LOD) and limit of quantitation (LOQ) are important factors in 
the analysis of THC and its analytes. Limit of Detection is defined as the lowest 
concentration that can be accurately depicted in an analyte screen. The limit of detection is 
the analyte concentration that can be reliably distinguished from zero40. In order to 
determine this limit, matrix samples of decreasing concentration were run in order to 
determine the lowest point of detection. The calculated LOD and LOQ was determined by 
analysis of four calibrators (0.25, 0.50, 1, 2 ng/mL) over a minimum of two runs to meet 
all detection and identification criteria. LOD was completed according to American 
Standards Board (ASB)41.  LOD values can be found in Table 8. 
Limit of quantitation is the lowest concentration in which defined analytes can be 
detected and quantified in regards to pre-determined criteria. Limit of quantitation can be 
equal to or greater than the limit of detection42. This threshold is the lowest point where 
the method can operate with acceptable precision41. Determination of LOQ data began by 





 x 100 
 
According to ASB Standard Practices for Method Validation in Forensic Toxicology, the 
%CV should not exceed 20%. In certain well-established methods %CV should be 
maintained around 10%. Because the analysis of tear fluid is a novel matrix, the %CV was 
evaluated using the 20% threshold. CV% can be found in Table 10. 
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Due to the novelty of use of tear fluid, it was necessary to understand the limitations 
to what could and could not be detected and quantitated with the existing procedure. It is 
necessary to be able to quantitate accurately and precisely within a specific matrix. In many 
states, presence of analyte can be enough to prosecute due to zero tolerance statutes1. 
States, such as Colorado, that maintain cutoffs in concentration need accurate measures of 
quantitation1. Colorado maintains a 5 ng/ml permissible inference for THC in DUID 
investigations. Knowledge of quantitative concentrations is a necessary factor for this 
analysis.  
It was of benefit to evaluate LOD and LOQ data at a lower concentration than the 
lowest calibrator. In order to maintain a consistency to data found in tests of current 
admissible matrices such as blood and oral fluid, 0.25 ng/mL was added as another point 
for determination of LOD and LOQ. LOD values were found to be around the 0.25 ng/mL 
value whereas the LOQ values were determined to be higher as seen in Tables 11 and 12. 
 
 







 0.25 ng/mL .5 ng/mL 1 ng/mL 2 ng/mL 
Batch 1 0.152 N/D 1.684 1.413 
Batch 2 0.184 N/D 0.065 1.913 
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 0.25 ng/mL .5 ng/mL 1 ng/mL 2 ng/mL 
Batch 1 N/D N/D N/D N/D 
Batch 2 N/D N/D N/D 2.000 
 0.25 ng/mL .5 ng/mL 1 ng/mL 2 ng/mL 
Batch 1 < 0 1.088 1.421 1.475 
Batch 2 0.257 0.484 N/D 2.009 
Analyte 0.25 ng/mL .5 ng/mL 1 ng/mL 2 ng/mL 
THC 9.52% N/D 92.53% 15.03% 
11-OH-THC N/D N/D N/D N/D 
THCCOOH N/D 38.42% N/D 15.33% 
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Compound Limit of Detection (ng/mL) Detected Concentration 
THC 0.25  
0.15 
0.18 
11-OH-THC 2.00  2.00 
THCCOOH 0.25  0.26 
Compound Limit of Quantitation (ng/mL) %CV 
THC 0.25  9.52% 
11-OH-THC N/D N/D 




 Evaluation of carryover in detection procedure was completed by analysis of blank 
matrix prior to the injection of the highest calibrator in triplicate. Per the existence of 
carryover, the value can be calculated with the following equation: 
 
%Carryover=
Average Peak Area (Blank)
Average Peak Area (Calibrator 9)
 x 100 
 
 
Carryover was examined throughout the five calibration runs evaluating the blank samples 
following the highest calibrator concentration at 250 ng/mL. Within the blank samples of 
the five runs there existed no ion detection at any of the analyte’s retention times. For 
example, a presence of carryover for THC would have yielded a peak around 4.88 in the 
blank sample. No carryover was detected for any of the three analytes, therefore no 
calculations were made.  
 
3.3 Patient Samples: Detection and Quantitation of Analytes 
The primary goal for this procedure was to better understand the novel matrix of 
tear fluid in detection of the targeted cannabinoids. Understanding that there could be a 
potential lack of quantitation due to the limited sample volume, detection was the primary 
goal. However, quantitative results were evaluated considering similarities of existing 
matrices, such as oral fluid, to tear fluid.  
Data was analyzed through two methods of evaluation. Primarily, the charted 
retention times vs analyte intensities were evaluated for the existence of peaks within the 
expected range. This expected range came from the calibration data as well as internal 
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standard comparison. The goal was to observe peaks around the expected retention time 
for detection and to observe the area of those peaks to gather quantitative data. The data 
was then plotted on the calibration curves in order to perform quantitative analysis.  
 
Each spectrum was observed individually in the initial examination. Each patient 
sample had three spectra, one for each target analyte, each measuring retention time and 
analyte intensity. Although the route of administration, smoking, was the same for every 
patient, the amount of inhaled drug varied from person to person to reach desired 
intoxicating levels. In this regard, those who took part as volunteers filled out surveys as 
to their use of Marijuana. There were obvious recorded differences in consistent general 
use, some being chronic users where as others having social or sporadic tendencies of use. 
All of this was considered in analysis. 
Once the initial analysis took place, patient sample data was compared to produced 
calibration curves within the Simplicity software. This helped produce an understanding 
about quantitative results in tear fluid. From previous LOD and LOQ calculations, 
quantitation for the main target analytes could hypothetically be observed in patient 
samples above 1 ng/mL. Although it was not the primary objective, quantitation values are 
of extreme benefit. 
When evaluating the data of patient samples, the procedure was sufficient in 
detection of THC and THCCOOH. There were complications in the detection of 11-OH-
THC due to the existence of a strong peak at approximately 5.05 min retention time. This 
was not indicative of any target analyte. When conducting an initial examination of the 
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spectrum, there was a peak that was consistent with the expected retention time range for 
the THC analyte as well as the THCCOOH analyte. This is outlined in Figures 9-11. 
Figure 8 depicts a baseline tear sample of one participant. 
 
Table 13: Blood Cannabinoid Concentration Results – Patient 13 
 
Collected Matrix  Concentration ng/mL Lab Cutoffs ng/mL 
Blood 
THC 31 0.50 
11-OH-THC 5.8 1.0 
THCOOH 54 5.0 
 
 





























4.1 Complications of a Novel Matrix 
  Working with a novel matrix poses complications as there is limited information 
on its application to toxicological testing. When referencing other journals about 
chromatography/mass spectrometry methods for detecting components of tear fluid, 
although there was evidence that the fluid could be analyzed with this method, methods for 
detecting drug analytes in tear fluid was effectively non-existent.  
The first obstacle was the collection of tear fluid. There was a common 
misconception in general understanding that the subject would have to produce an 
emotional response to produce collectable tears. As stated in Section 1.3, glands are 
constantly producing fluid, in the form of water and sebum, to maintain moisture in the 
environment of the eye. The most probative location for collection was determined to be 
the lower eyelid for its ease of access, concentration of fluid, and location of meibomian 
glands.  
The next question to answer was the method of collection. Schirmer paper strips 
are a technology used in the ophthalmological community in order to test for DED. A strip 
will collect tear fluid through capillary action to show the individuals ability to produce 
tears. Schirmer paper strips were utilized in Schirmer Paper Noninvasive Microsampling 
for Direct Mass Spectrometry Analysis of Human Tears by Yao et al. in congruence with 
Paper Spray-MS/MS43. It was hypothesized that this collection method would have 
parallels to a method utilizing LC/MS. The method listed in Yao et al. analyzed 
environmental exposures and certain drug analytes. Mentioned in the paper, the collection 
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of tear fluid with the Schirmer paper has complications because of low collected sample 
volume43. This was found to be the case in this study as well. The Schirmer paper was able 
to fully saturate at approximately 30-50 ul, an exceptionally low sample volume for 
detection. 
Polyvinyl Alcohol (PVA) and cellulose were considered as alternative collection 
material. Used in drug matrix collection tests, such as Quantisal® Oral Fluid drug analyte 
tests, cellulose was proven to be a material with great collection ability and low interference 
with THC and related cannabinoids38. PVA was used in ophthalmological DED tests, 
manufactured by Inflammadry® and had shown efficacy in absorption/collection of tear 
fluid specifically. Both materials were available in isolated strip form.  
Both materials were tested on the ability to: collect the fluid at high sample volume, 
be able to release the analyte in an extraction step and maintain low interference with the 
target analyte for good peak identification and quantitation. Cellulose, used in congruence 
with extraction buffer, was the best at filling these three criteria. The cellulose strips cut to 
the dimensions of the lower eyelid were able to retain approximately 200 ul of sample 
volume, a significant increase in volume from the Schirmer paper. 
 
4.2 Sample Preperation: Extraction  
While building the sample preparation method, past research was referenced to 
guide the extraction of drug analyte in a matrix. As previously stated, sample preparation 
for Paper Spray MS was an adequate way of utilizing Schirmer paper strips as a collection 
mechanism43. The two problems that posed included the unavailability of Paper Spray MS 
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and the small sample volume collection abilities of Schirmer paper strips. Although it was 
evident that the strips were not of value in the collection process, it was still questioned 
whether it was an issue with extraction solvent rather than the sample volume size.  
Initially, a standard methanol extraction was used. However, when extracting with 
methanol, signal intensity within the calibrators was either low or non-existent. This 
extraction inconsistency was not sufficient enough to retain information. All of the ordered 
drug standards and working stock are preserved and diluted with methanol in order to reach 
the desired concentration for calibration. Because of the extraction with methanol, there 
could have existed a possible dilution. Sample volumes, between 50-200 uL, is low and 
any dilution could pose issues. Schirmer paper strips were only able to retain 30-50 uL of 
sample. Therefore, more dilution would limit the amount of analyte that could be detected. 
Procedures with matrices that are known for interfering with detection utilize solid 
phase extraction elution columns that separate analyte from interferences. This method was 
evaluated with tear fluid collected in Schirmer paper strips, however, like methanol results 
were either inconsistent or non-existent. There could be a multitude of reasons why the 
columns were not effective in the recovery of analytes, however it is believed that the issue 
was once again with dilution of low sample volume. It was found that a stable buffer helped 
to ensure the proper detection of analytes. Quantisal oral fluid collection devices 
(Immunalysis, Pomona, California, USA) are devices that ready an oral fluid sample for 
downstream drug detection. The collection material, a wand with a cellulose tip, saturates 
with oral fluid and is placed in extraction buffer that extracts and stabilizes the drug analyte. 
It was hypothesized that this action could be replicated in the analysis of tear fluid. Using 
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the buffer material, analyte was extracted and stabilized to detect adequate levels of 
primary analyte, THC.  
 
4.3 Filter Vials 
 There are different methods of sample preparation that can be utilized in LC/MS 
procedures. Traditional methods include solid phase or liquid/liquid extraction.  
These methods act as purifying steps in which unwanted portions of the sample, such as 
matrix interferences, are removed or reduced from the sample and can be disposed of 
properly. Matrices, such as blood, have different components in which interferences can 
be problematic to analysis.  
 Since collected samples were low in sample volume, a complex sample preparation 
method posed issues surrounding dilution and loss of analyte. Multi-step processes 
decreased retention of analyte significantly. This allowed for the pursuit of simplified 
methods that would maintain sample volume. Thompson Filter Vials with a Quantisal 
buffer solution were used in the procedure as the technology allowed for separation of 
analyte from collection material while retaining the original sample. The vial system 
worked on a compression mechanism where solution was placed in a base vial. The top 
component worked as a compressible plunger that forced sample into a top chamber 
through a selected filter. The ability to remove original sample in buffer from collection 
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material and allowing for filtration was deemed beneficial and allowed for direct analysis 
by LC-MS/MS. 
 
4.4 Source Polarity: Positive and Negative Ionization  
In previous research, the method optimization parameters were set in positive 
ionization mode. In MS Electrospray Ionization methods positive ionization is usually the 
preferred method and was utilized in the detection procedure. Research has shown with 
certain analytes and methods that negative ionization has produced a stronger analysis than 
positive ionization44. In Think Negative: Finding the Best Electrospray Ionization/MS 
Mode for Your Analyte by Piia Liigand et al., it was determined that negative ionization 
produced better results and higher sensitivity in the majority of compounds that they 
analyzed44. Negative ionization was run for all analytes at median calibrations in order to 
reach a better specificity and resolution of result. Negative ionization was not effective in 
the MS method as the data was either low in signal intensity or nonexistent. 
 
 
4.5 The First Analysis of Patient Sample 13 
 Patient samples were analyzed one at a time because of the limited number of 
samples at the time of analysis. The first patient sample analyzed was ran with one of the 
last calibrations runs and was run after a sample blank to ensure no carryover. When 
evaluating the data of a patient sample, it was noted that THC could be detected at a peak 
intensity of approximately 4,000 cps, a peak area of 5,513 counts, and a retention time of 
4.875 minutes. These criteria were all indicative of the confirmed presence of THC due to 
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peak intensity corresponding to specific MRM transitions and quantitative and qualitative 
ion ratios. When examining the baseline data, which was expected to be no presence of any 
analyte, there was a significantly smaller peak at a retention time of 4.89 and an intensity 
of approximately 700. The first thought of seeing the peak for THC in the baseline data 
would be a product of carryover. However, from the carryover analysis, the procedure did 
not have any evidence that carryover would pose any problems.  
Participants were asked to abstain from partaking in any dosing before baseline data 
was taken, however it is difficult to enforce these rules when the subject cannot be under 
supervision. According to the baseline survey data for patient 13, the answers indicated 
potential chronic use. It is known that THC analyte can be detectable in chronic users for 
up to 72 hours after use and the peak within the baseline is believed to be a byproduct of 
this occurrence.  
 
4.6 Sample Volume & LOD/LOQ 
 In specific after dose patient samples, patients 10-12, it was seen that there was an 
ability to detect analyte however there was trouble in quantitating data. This patient data 
can be found in Appendix A. There are a few explanations for this occurrence. The primary 
explanation is the variation of sample volume in each collection. It was observed that each 
patient had a variation of tolerance for placing the cellulose under the eyelid. Individuals 
who regularly use products, such as contacts, are used to the changes in the eye 
environment when something is placed on or around it. Patient 13, who had the best 
results/peak intensity, was the sole contact wearer in the group of 4 (patients 10-13). The 
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other three patients were in discomfort and quickly wanted the cellulose to be removed. 
Although the two strips collect approximately 200 l of matrix, there is variability on 






 The hypothesis for this procedure was based on the lipid rich nature of the 
meibomian layer of tear fluid. The lipophilic nature of cannabinoid analytes, THC, 11-OH-
THC, and THCCOOH, help facilitate detection of these analytes in fluids and tissues that 
are lipid rich. The existence of the meibomian layer as well as FABP5 in tear fluid, the 
novel matrix was a point of exploration that was deemed beneficial to cannabinoid 
detection. A method that collects this matrix in an extraction buffer for stability was shown 
to be an efficient and effective way to retain the analyte allowing for direct injection and 
subsequent analysis by LC-MS/MS. It was made clear that THC analytes could be detected 
and quantitated at levels as low as 0.25 ng/mL and THCCOOH could be detected at 0.25 
ng/mL and quantitated at 1 ng/mL with the developed procedures. There arose 




5.1 Future Directions 
The detection of target analyte, THC, in tears may be a probative measure that has 
potential use for toxicological analysis. However, there are aspects of the analysis that can 
be modified to a degree that would create a more effective method for quantitation. It would 
be of benefit to attempt different modes of ionization as studies show that there can be 
increased sensitivity and selectivity. Although negative ionization did not show to be an 
effective method, with the altered collection methods and MS parameters these factors 
could have a beneficial outcome. Similarly, it would be interesting to explore different 
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extraction methods. Standard direct injection with the aid of extraction buffer was 
sufficient to detect and quantify analytes to a degree. It could be of benefit to explore other 
extraction methods to optimize the procedure. 
It would be of benefit to complete tests on a larger group of participants in order to 
further optimize detection and quantitation. This study was focused on the ability to detect 
and quantitate; therefore, it was not priority to collect tears at different time points. 
However, it would be of extreme benefit to do so.  
 Utilizing the current procedure, it would be of benefit to cultivate and optimize 
these methods into tools to aid in roadside DUID enforcement. The development of 
technologies to create  roadside detection tools is a current topic in impairment assessment. 
Because of the issues that arise with current methods of detection, the use of tear fluid may 
be a simplified and non-invasive collection tool that could be of use in law enforcement 
agencies. This tool could allow law enforcement to detect drug analyte in a manner as 





APPENDIX A:  [Results from collected patient data] 
 
Collected Matrix  Concentration ng/mL Lab Cutoffs ng/mL 
Blood 
THC 3.4 0.50 
11-OH-THC N/D 1.0 
THCOOH   
 
 




Data Collected After Dose Patient 10 – THC  
 
 




Collected After Dose Patient 10 – 11-OH-THC 
 
 





























Baseline Data Patient 11 – THC  
 
Collected Matrix  Concentration ng/mL Lab Cutoffs ng/mL 
Blood 
THC 6.6 0.50 
11-OH-THC 1.5 1.0 




 Data Collected After Dose Patient 11 - THC 
 
 







Data Collected After Dose Patient 11 – 11-OH-THC 
 
  










Patient 12 Data: 
 
Collected Matrix  Concentration ng/mL Lab Cutoffs ng/mL 
Blood 
THC 2.1 0.50 
11-OH-THC N/D 1.0 
THCOOH   
 
 











































Appendix B: Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis 
Use Inventory (DFAQ-CU) 
DFAQ-CU Inventory 
Instructions: Please read each of the following questions and mark the response alternative that 
best describes your use of cannabis. Note that the term cannabis is being used to refer to 
marijuana, cannabis concentrates, and cannabis-infused edibles.  
 
1. Have you ever used cannabis? 
0 = No 
1 = Yes 
 
*If response = 0 then skip to end of questionnaire 
 
2. Which of the following best captures when you last used cannabis? 
1 = over a year ago 
2 = 9 – 12 months ago  
3 = 6 – 9 months ago 
4 = 3 – 6 months ago  
5 = 1 – 3 months ago  
6 = less than 1 month ago 
7 = last week 
8 = this week 
9 = yesterday 
10 = today* 
11 = I am currently high* 
 
*If response = 10 (today) or 11 (I am currently high) then answer 2b below  
 
2b. How high are you right now?  
0 = I am not at all high 
1 = I am a little bit high 
2 = I am moderately high 
3 = I am very high 
4 = I am extremely high 
 
3. Which of the following best captures the average frequency you currently use cannabis?  
0 = I do not use cannabis 
1 = less than once a year 
2 = once a year 
3 = once every 3-6 months (2-4 times/yr)) 
4 = once every 2 months (6 times/yr) 
5 = once a month (12 times/yr) 
6 = 2 – 3 times a month 
7 = once a week 
8 = twice a week 
9 = 3 – 4 times a week  
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10 = 5 – 6 times a week 
11 = once a day 
12 = more than once a day 
 
4. Which of the following best captures how long you have been using cannabis at this 
frequency? 
1 = less than 1 month 
2 = 1 – 3 months 
3 = 3 – 6 months 
4 = 6 – 9 months 
5 = 9 – 12 months 
6 = 1 – 2 years 
7 = 2 – 3 years 
8 = 3 – 5 years 
9 = 5 – 10 years 
10 = 10 – 15 years 
11 = 15 – 20 years 
12 = more than 20 years
5. Before the period of time you indicated above, how frequently did you use cannabis? 
0 = I did not use cannabis 
1 = less than once a year 
2 = once a year 
3 = once every 3-6 months (2-4 times/yr.) 
4 = once every 2 months (6 times/yr.) 
5 = once a month  
        6 = 2 – 3 times a month 
7 = once a week 
8 = twice a week 
9 = 3 – 4 times a week  
10 = 5 – 6 times a week 
11 = once a day 
12 = more than once a day
 
6. How many days of the past week did you use cannabis? 
 0 = 0 days 
 1 = 1 day 
 2 = 2 days 
 3 = 3 days 
 4 = 4 days 
 5 = 5 days 
 6 = 6 days 
 7 = 7 days 
 
7. Approximately how many days of the past month did you use cannabis? ____________ 
 
8. Which of the following best captures the number of times you have used cannabis in your 
entire life? 
1 = 1 – 5 times in my life 
2 = 6 – 10 times in my life 
3 = 11 – 50 times in my life 
4 = 51 –100 times in my life 
5 = 101 – 500 times in my life 
6 = 501 – 1000 times in my life 
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7 = 1001 – 2000 times in my life 
8 = 2001 – 5000 times in my life 
9 = 5001 – 10,000 times in my life 
10 = More than 10,000 times in my life 
 
9. Which of the following best captures your pattern of cannabis use throughout the week? 
0 = I do not use cannabis at all 
1 = I only use cannabis on weekends 
2 = I only use cannabis on weekdays 
3 = I use cannabis on weekends and weekdays 
 
10. How many hours after waking up do you typically first use cannabis? 
 0 = I do not use cannabis at all 
1 = 12 – 18 hours after waking up 
 2 = 9 – 12 hours after waking up 
 3 = 6 – 9 hours after waking up 
 4 = 3 – 6 hours after waking up 
 5 = 1 – 3 hours after waking up 
 6 = within 1 hour of waking up 
 7 = within ½ hour of waking up 
 8 = immediately upon waking up
 
11. How many times a day, on a typical weekday, do you use cannabis? ____________ 
 






13. What is the primary method you use to ingest cannabis? 
0 = I do not use cannabis 
1 = Joints 
2 = Blunts (cigar sized joints) 
3 = Hand pipe 
4 = Bong (water pipe)  
5 = Hookah 
6 = Vaporizer (e.g., Volcano, Vape pen)  
7 = Edibles  




14. Which of the following other methods to ingest cannabis do you use regularly (at least 25% 
of the time use you cannabis)? [Mark all that apply] 
0 = None 
1 = Joints 
2 = Blunts (cigar sized joints) 
3 = Hand pipe 
4 = Bong (water pipe)  
5 = Hookah 
6 = Vaporizer (e.g., Volcano, Vape pen)  
7 = Edibles  
8 = Other _______________________
 
15. What is the primary form of cannabis you use? 
0 = None**** 
A = Marijuana*** 
B = Concentrates (e.g., Oil, Wax, Shatter, Butane Hash Oil, Dabs)** 
C = Edibles* 
D = Other____________________  
 
16. What other forms of cannabis do you use regularly (at least 25% of the time you use 
cannabis)? [Mark all that apply] 
0 = None**** 
A = Marijuana*** 
B = Concentrates (e.g., Oil, Wax, Shatter, Butane Hash Oil, Dabs)** 
C = Edibles* 
D = Other____________________ 
 
****If response to questions 15 and 16 = 0 (None) then skip to question 29 
***If responses to questions 15 or 16 = A (Marijuana) then answer questions 17-21 
**If responses to question 15 or 16 = B (Concentrates) then answer questions 22-26 
*If responses to question 15 or 16 = C (Edibles) then answer question 27  




***If responses to questions 15 or 16 = A (Marijuana) then answer questions 17-21 below. 
 
Please use the image below to refer to various quantities of marijuana. The image is not to scale; 




For questions 17 to 19 below, clearly indicate the number of grams of marijuana you use with a 
number between 0 – 100. Do NOT include other forms of cannabis you may use (such as 
concentrates). You may use up to 3 decimals to indicate amounts under 1 gram.  
 
Note: 1/8 of a gram = 0.125 grams, ¼ of a gram = 0.25 grams, ½ of a gram = 0.5 grams, ¾ of a 
gram = 0.75 grams. 1/8 of a ounce = 3.5 grams, ¼ of an ounce = 7 grams, ½ ounce = 14 grams, 1 
ounce = 28 grams 
 




18. On a typical day you use marijuana, how much do you personally use? _________________ 
 
19. In a typical week you use marijuana, how much marijuana do you personally use? ________ 
 
20. On a typical day you use marijuana, how many sessions do you have? __________________ 
21. What is the average THC content of the marijuana you typically use? Leave blank if you do 
not know. 
 1 = 0 – 4%  
2 = 5 – 9%  
 3 = 10 – 14% 
 4 = 15 – 19% 
 5 = 20 – 24% 
 6 = 25 – 30% 
  7 = greater than 30% 
 
 
**If response to questions 15 or 16 = B (Concentrates) then answer questions 22-26 below 
 
22. In a typical session you use cannabis concentrates, how many hits do you personally take? __ 
 
23. On a typical day you use cannabis concentrates, how many hits do you personally take? ____ 
 
24. How many hits of cannabis concentrates did you personally take yesterday? _____________ 
 
25. On a typical day you use cannabis concentrates, how many sessions do you have? _________  
 
26. What is the average THC content of the concentrates you typically use? Leave blank if you do 
not know. 
1 = 0 – 9% 
2 = 10 – 19%  
3 = 20 – 29% 
4 = 30 – 39% 
 5 = 40 – 49% 
 6 = 50 – 59% 
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7 = 60 – 69% 
 8 = 70 – 79% 
 9 = 80 – 90% 
 10 = greater than 90%
 
 
**If response to questions 15 or 16 = C (Edibles) then answer question 27 below 
 




28. What is your current age? ___________ 
 
29. How many years in total have you used cannabis? ___________ 
 
30. How old were you when you FIRST tried cannabis? ___________ 
 
31. Has there been any time in your life when you used cannabis regularly (2 or more times per 
month for 6 months or longer)? 
0 = No 
1 = Yes* 
 
*If response = 1 (Yes) then answer questions 31b and 31c below 
 




31c. Has there been any time in your life when you used cannabis on a daily or near daily 
basis for 6 months or longer? 
0 = No 
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1 = Yes* 
 
*If response = 1 (Yes) then answer question 31ci below 
 
31ci. How old were you when you FIRST STARTED using cannabis on a daily 
or  
 
near daily basis? ___________ 
 
32. Which of the following best captures the average frequency that you used cannabis before the 
age of 16?  
0 = more than once a day 
1 = once a day 
2 = 5 – 6 times a week 
3 = 3 – 4 times a week 
4 = twice a week 
5 = once a week 
6 = 2 – 3 times a month 
7 = once a month 
8 = once every 2 months (6 times/yr.) 
9 = once every 3-6 months (2-4 times/yr.) 
10 = once a year 
11 = less than once a year 
12 = never
 
33. Do you have a physician’s recommendation to use cannabis for medicinal purposes?  
0 = No 
1 = Yes* 
2 = Yes, but I use it for both medicinal and recreational purposes* 
 
*If response = 1 or 2 (Yes) then answer questions 33b and 33c 
 










Daily Sessions Items: 20, 25 
Frequency Items: 2, 3, 6, 7, 8, 9, 10, 11, 12 
Age of Onset Items: 30, 31b, 31ci, 32 
Marijuana Quantity Items: 17, 18, 19 
Concentrate Quantity Items: 22, 23, 24,  
Edibles Quantity Item: 27  
Note: Standardize (z-transform) scores prior to calculating the mean of each of the 6 factors 
(daily sessions, frequency, age of onset, marijuana quantity, concentrate quantity, edibles 
quantity). 
 
Screening/Characterization Items: 1, 2b, 4, 5, 13, 14, 15, 16, 21, 26, 28, 29, 31, 31c, 33, 33b, 33c 
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